Long-Term Prognosis of Japanese Patients with Crohn’s Disease Treated by Switching Anti-Tumor Necrosis Factor-α Antibodies
-
Published:2019-12-20
Issue:1
Volume:5
Page:11-19
-
ISSN:2296-9403
-
Container-title:Inflammatory Intestinal Diseases
-
language:en
-
Short-container-title:Inflamm Intest Dis
Author:
Moroi Rintaro, Shiga Hisashi, Endo Katsuya, Yamamoto Katsutoshi, Kuroha Masatake, Kanazawa Yoshitake, Kakuta Yoichi, Kinouchi Yoshitaka, Masamune AtsushiORCID
Subject
Aerospace Engineering
Reference27 articles.
1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012 Nov;380(9853):1590–605. 2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al.; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May;359(9317):1541–9. 3. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2):323–33. 4. Sands BE, Blank MA, Patel K, van Deventer SJ: Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:912–20. 5. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007 Jan;132(1):52–65.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|